Table 2.
Hormonal status, biomarkers of inflammation and oxidative stress at baseline and after the 12-week intervention in subjects with polycystic ovary syndrome
| Placebo group (n = 30) | Synbiotic group (n = 30) | pa | |||||
|---|---|---|---|---|---|---|---|
| Baseline | End-of-trial | Change | Baseline | End-of-trial | Change | ||
| Total testosterone (ng/mL) | 2.4 ± 1.2 | 2.3 ± 1.0 | −0.1 ± 0.5 | 2.8 ± 1.3 | 2.4 ± 0.9 | −0.4 ± 0.9 | 0.09 |
| SHBG (nmol/L) | 38.3 ± 17.3 | 38.8 ± 17.6 | 0.5 ± 5.4 | 37.3 ± 13.1 | 57.1 ± 48.6 | 19.8 ± 47.3 | 0.01 |
| FAI | 0.27 ± 0.21 | 0.25 ± 0.16 | −0.01 ± 0.08 | 0.33 ± 0.36 | 0.21 ± 0.14 | −0.12 ± 0.29 | 0.01 |
| mF-G scores | 15.1 ± 3.8 | 15.0 ± 3.7 | −0.1 ± 0.5 | 15.3 ± 5.6 | 14.0 ± 4.9 | −1.3 ± 2.5 | 0.01 |
| DHEAS (μg/mL) | 2.6 ± 1.3 | 2.5 ± 1.1 | −0.1 ± 0.4 | 2.6 ± 1.5 | 2.2 ± 0.8 | −0.4 ± 1.1 | 0.40 |
| hs-CRP (ng/mL) | 2990.7 ± 2510.7 | 3326.0 ± 2791.1 | 335.3 ± 2466.9 | 2920.0 ± 2251.2 | 1970.0 ± 1442.0 | −950.0 ± 2246.6 | 0.02 |
| NO (μmol/L) | 40.5 ± 8.7 | 40.8 ± 9.3 | 0.3 ± 9.1 | 39.0 ± 3.1 | 44.5 ± 5.0 | 5.5 ± 4.8 | 0.006 |
| TAC (mmol/L) | 868.7 ± 158.4 | 877.9 ± 149.9 | 9.2 ± 119.3 | 773.1 ± 38.7 | 818.2 ± 57.5 | 45.1 ± 51.8 | 0.13 |
| GSH (μmol/L) | 494.2 ± 85.5 | 521.5 ± 117.2 | 27.3 ± 117.8 | 498.9 ± 56.8 | 523.5 ± 53.4 | 24.7 ± 58.7 | 0.91 |
| MDA (μmol/L) | 2.2 ± 0.7 | 2.7 ± 1.2 | 0.5 ± 1.4 | 2.3 ± 0.4 | 2.1 ± 0.4 | −0.2 ± 0.1 | 0.05 |
All values are means± SDs
aP values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA)
DHEAS dehydroepiandrosterone sulfate, FAI free androgen index, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, mF-G modified Ferriman Gallwey, MDA malondialdehyde, NO nitric oxide, SHBG sex hormone-binding globulin, TAC total antioxidant capacity